You have 9 free searches left this month | for more free features.

Capecitabine

Showing 1 - 25 of 2,332

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Breast Cancer Trial in Beijing (Mitoxantrone HCl liposome, Capecitabine)

Not yet recruiting
  • Breast Cancer
  • Mitoxantrone hydrochloride liposome
  • Capecitabine
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Dec 1, 2023

Pancreas Cancer, Pancreas Adenocarcinoma Trial in Cleveland (Capecitabine)

Not yet recruiting
  • Pancreas Cancer
  • Pancreas Adenocarcinoma
  • Capecitabine
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Seidman Cancer Ce
Oct 29, 2023

to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally

Recruiting
  • to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally Advanced Hypopharyngeal Carcinoma
  • Capecitabine 500Mg Oral Tablet
  • Shanghai, China
    Eye & ENT Hospital, Fudan University
Jul 2, 2023

Triple Negative Breast Cancer, Residual Disease Trial (Tetrathiomolybdate, Capecitabine, Pembrolizumab)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Residual Disease
  • (no location specified)
Nov 15, 2023

Recurrent Metastatic Nasopharyngeal Carcinoma Trial (Mitoxantrone HCl liposome injection, Capecitabine)

Not yet recruiting
  • Recurrent Metastatic Nasopharyngeal Carcinoma
  • Mitoxantrone hydrochloride liposome injection
  • Capecitabine
  • (no location specified)
Jan 29, 2023

Gastrointestinal Cancer Trial (Capecitabine, Sacituzumab govetican)

Not yet recruiting
  • Gastrointestinal Cancer
  • Capecitabine
  • Sacituzumab govetican
  • (no location specified)
Oct 2, 2023

Recurrent or Metastatic Colorectal Cancer Trial (Nelmastobart and Capecitabine)

Not yet recruiting
  • Recurrent or Metastatic Colorectal Cancer
  • Nelmastobart and Capecitabine
  • (no location specified)
Aug 6, 2023

Metastatic Breast Cancer Trial in Birmingham (Capecitabine Pill)

Not yet recruiting
  • Metastatic Breast Cancer
  • Capecitabine Pill
  • Birmingham, Alabama
    University of Alabama at Birmingham
Oct 23, 2023

Colorectal Carcinoma Trial (Fruquintinib?Capecitabine Tablets)

Not yet recruiting
  • Colorectal Carcinoma
  • Fruquintinib、Capecitabine Tablets
  • (no location specified)
Oct 30, 2023

Breast Cancer Stage I Trial (Capecitabine,Pyrotinib)

Not yet recruiting
  • Breast Cancer Stage I
  • (no location specified)
May 7, 2023

Metastatic Colorectal Cancer Trial in Guangzhou (Fruquintinib alternating with Bevacizumab plus Capecitabine, Bevacizumab plus

Recruiting
  • Metastatic Colorectal Cancer
  • Fruquintinib alternating with Bevacizumab plus Capecitabine
  • Bevacizumab plus Capecitabine
  • Guangzhou, Guangdong, China
    Nanfang Hospital, Southern Medical University
Jan 4, 2023

Metastatic Colorectal Cancer Trial in Guangzhou (Cetuximab, Capecitabine)

Recruiting
  • Metastatic Colorectal Cancer
  • Guangzhou, Guangdong, China
    The Sixth Affiliated Hospital of Sun Yat-sen University
Mar 7, 2023

Head and Neck Squamous Cell Carcinoma Trial (Carrilizumab, bevacizumab,capecitabine)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Carrilizumab, bevacizumab,capecitabine
  • (no location specified)
Jul 20, 2023

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2

Recruiting
  • HER2-positive Breast Cancer
  • Early-stage Breast Cancer
  • pyrotinib combined with Capecitabine
  • treatment of physician's choice
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 6, 2023

Advanced Gastric Carcinoma Trial in Dhaka (Trastuzumab, Oxaliplatin, Capecitabine)

Completed
  • Advanced Gastric Carcinoma
  • Dhaka, Bangladesh
    Bangabandhu Sheikh Mujib Medical University
Aug 15, 2023

Triple Negative Breast Tumors Trial (Pembrolizumab injection, Capecitabine tablets, Local radiotherapy)

Not yet recruiting
  • Triple Negative Breast Neoplasms
  • Pembrolizumab injection
  • +2 more
  • (no location specified)
Jul 25, 2023

Breast Cancer Trial in Xi'an (Inetetamab plus pyrotiniband and capecitabine)

Active, not recruiting
  • Breast Cancer
  • Inetetamab plus pyrotiniband and capecitabine
  • Xi'an, Shaanxi, China
    Xi'an International Medical Center Hospital
Aug 27, 2023

Breast Cancer With Brain Metastases Trial in Wuhan (pyrotinib+capecitabine+bevacizumab)

Recruiting
  • Breast Cancer With Brain Metastases
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 22, 2023

Breast Cancer Trial (SHR-A1811 for injection ; capecitabine)

Not yet recruiting
  • Breast Cancer
  • SHR-A1811 for injection ; capecitabine
  • (no location specified)
May 4, 2023

Breast Cancer Trial in Beijing (oral vinorelbine and capecitabine)

Recruiting
  • Breast Cancer
  • oral vinorelbine and capecitabine
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Feb 27, 2023

Gastric Cancer, Adjuvant Chemo, XO Trial in Seoul (Docetaxel and capecitabine and oxaliplatin, capecitabine and oxaliplatin)

Recruiting
  • Gastric Cancer, Adjuvant Chemotherapy, XO
  • Docetaxel and capecitabine and oxaliplatin
  • capecitabine and oxaliplatin
  • Seoul, Korea, Republic of
    Asan Medical Center
Dec 30, 2022

Nasopharyngeal Tumors Trial (The combination treatment of anlotinib, penpulimab and capecitabine.)

Not yet recruiting
  • Nasopharyngeal Neoplasms
  • The combination treatment of anlotinib, penpulimab and capecitabine.
  • (no location specified)
Apr 10, 2023

Nasopharyngeal Carcinoma Trial in Singapore (CCRT with Maintenance Tislelizumab and Metronomic Capecitabine)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • CCRT with Maintenance Tislelizumab and Metronomic Capecitabine
  • Singapore, Singapore
  • +1 more
Oct 16, 2023

HER2 Positive Metastatic Breast Cancer Trial in Beijing (pyrotinib, , Capecitabine)

Active, not recruiting
  • HER2 Positive Metastatic Breast Cancer
  • Beijing, China
    307 Hospital Affiliated to Academy Military Medical Science
Oct 24, 2022

Unresectable/Metastatic Colorectal Cancer Trial in Guangzhou (Fruquintinib plus camrelizumab and capecitabine)

Recruiting
  • Unresectable/Metastatic Colorectal Cancer
  • Fruquintinib plus camrelizumab and capecitabine
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Nov 19, 2023